Health Care • Biotechnology: Pharmaceutical Preparations
$46.39 ▼ -0.43
(-0.92%)
MKT CAP: $133.3M • VOL: 66.0K
52W L $38 52W H $129
SPRB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $4.9M | $10.1M |
| YoY Revenue Growth % | — | -51.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$36.5M | -$56.2M | -$52.0M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$39.0M | -$53.0M | -$47.9M |
| EBITDA (Normalized) | — | -$56.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$33.3M | -$56.0M | -$33.3M |
| Capital Expenditures (CapEx) | — | $0 | — |
| Free Cash Flow (FCF) | -$33.3M | -$56.0M | -$33.3M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $48.9M | $38.8M | — |
| Total Debt (Short + Long Term) | $0 | $124.0K | — |
| Total Stockholders' Equity | $42.5M | $28.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SPRB.